NeuroRegen: In-Silico Design of Dual-Action Intranasal Nanoparticle Therapy for Alzheimer’s Disease

Overview

Alzheimer's disease affects over 55 million people, projected to double by 2050. Current pharmaceutical treatments including Donepezil and Memantine primarily alleviate symptoms without addressing neurodegeneration, and often cause toxic side effects. We propose a dual-action strategy combining Tropoflavin, a TrkB receptor agonist, and EF24, a tau-regulating curcumin analog, delivered intranasally via PLGA nanoparticles to effectively treat AD. Four computational experiments assessed molecular binding, safety, and pharmacokinetics. Molecular docking revealed Tropoflavin's strong TrkB affinity, while EF24 bound effectively to tau and GSK-3β. Molecular dynamics confirmed stable interactions over time that approved treatments could not maintain. ADME and toxicity analyses predicted favorable drug-like properties and low toxicity. Intranasal pharmacokinetic simulations demonstrated substantially greater brain bioavailability compared to oral administration. In-vitro synthesis of nanoparticles met pharmaceutical benchmarks for size, PDI and zeta potential. These results support NeuroRegen as a viable, non-invasive, disease-modifying treatment for AD with improved specificity.

Awards (2)

• Silver Medal
• Selected for CWSF 2026

Competition history

• CWSF 2026 Disease & Illness

Related projects

Closest projects by meaning, across every fair and year in the corpus.